GEN Exclusives

More »

GEN News Highlights

More »
Mar 5, 2007

GTC Signs Deal to Produce PharmaAthene’s Protexia

  • GTC Biotherapeutics and PharmAthene entered into an agreement under which GTC will provide process development and clinical supply manufacturing services for PharmAthene’s Protexia® program. Protexia is a recombinant form of human butyrylcholinesterase (rBChE) produced in the milk of transgenic goats that is being developed by PharmAthene as a pre and postexposure therapy for military or civilian victims of a chemical nerve agent attack.

    While human-plasma-derived butyrylcholinesterase’s (hBChE) ability to protect against nerve agent toxicity is well-documented, manufacturers have been unable to produce commercial quantities. According to PharmAthene, its rBChE enables substantially larger production yields than are possible through other methods. The company estimates that transgenic production and manufacturing is capable of supplying sufficient rBChE to make Protexia for use by the military and civilians.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Block That Microbiome Metaphor!

Which way of thinking about the microbiome would best integrate the virome’s contributions?